PACSIN1 promotes immunosuppression in gastric cancer by degrading MHC-I

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Gastric cancer (GC) is a prevalent gastrointestinal malignancy.
• PACSIN1 is implicated as an oncogene in various cancers.
• Understanding PACSIN1's role in GC is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate PACSIN1 as a potential therapeutic target in gastric cancer.
• To elucidate the mechanism by which PACSIN1 influences tumor immunity in GC.
• To assess the impact of PACSIN1 modulation on GC progression and treatment response.

Main Methods:

• Gene expression analysis (RT-qPCR, immunofluorescence, immunohistochemistry).
• Fluorescence in situ hybridization (FISH) for PACSIN1 and MHC-I colocalization.
• Flow cytometry for cytokine release and cell function analysis.
• In vivo studies including histological analysis (H&E staining).

Main Results:

• PACSIN1 is overexpressed in GC, particularly in immunologically-cold tumors, correlating with poor prognosis.
• PACSIN1 deficiency reduces autophagy but enhances antigen presentation and CD8+ T-cell infiltration.
• PACSIN1 inhibition suppresses tumor growth, liver metastasis, and improves sensitivity to immune checkpoint blockade.

Conclusions:

• PACSIN1 negatively regulates antitumor immunity in GC by controlling MHC-I lysosomal trafficking and antigen presentation.
• Targeting PACSIN1 represents a promising strategy to enhance anti-GC immune responses and therapeutic outcomes.